ADVFN ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Outlook Therapeutics Inc

Outlook Therapeutics Inc (OTLK)

1.76
0.08
(4.76%)
1.77
0.01
( 0.57% )

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Premium

Key stats and details

Current Price
1.77
Bid
1.71
Ask
1.76
Volume
183,672
1.69 Day's Range 1.78
0.87 52 Week Range 9.25
Market Cap
Previous Close
1.68
Open
1.71
Last Trade
1
@
1.71
Last Trade Time
16:14:59
Financial Volume
$ 319,190
VWAP
1.7378
Average Volume (3m)
545,753
Shares Outstanding
33,568,023
Dividend Yield
-
PE Ratio
-0.78
Earnings Per Share (EPS)
-2.25
Revenue
-
Net Profit
-75.37M

About Outlook Therapeutics Inc

Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications.

Sector
Biological Pds,ex Diagnstics
Industry
Biological Pds,ex Diagnstics
Headquarters
Dover, Delaware, USA
Founded
-
Outlook Therapeutics Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker OTLK. The last closing price for Outlook Therapeutics was $1.68. Over the last year, Outlook Therapeutics shares have traded in a share price range of $ 0.87 to $ 9.25.

Outlook Therapeutics currently has 33,568,023 shares outstanding. The market capitalization of Outlook Therapeutics is $56.39 million. Outlook Therapeutics has a price to earnings ratio (PE ratio) of -0.78.

OTLK Latest News

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1001.771.7751.653998991.68833712CS
40.1257.598784194531.6451.971.55067406461.80037205CS
120.5646.28099173551.212.0351.065457531.65960022CS
260.3524.64788732391.422.5951.066484661.78794776CS
52-5.86-76.80209698567.639.250.877928612.37273643CS
156-19.43-91.650943396221.240.60.87177255010.44658492CS
260-24.43-93.244274809226.285.20.87190375322.11677527CS

OTLK - Frequently Asked Questions (FAQ)

What is the current Outlook Therapeutics share price?
The current share price of Outlook Therapeutics is $ 1.77
How many Outlook Therapeutics shares are in issue?
Outlook Therapeutics has 33,568,023 shares in issue
What is the market cap of Outlook Therapeutics?
The market capitalisation of Outlook Therapeutics is USD 56.39M
What is the 1 year trading range for Outlook Therapeutics share price?
Outlook Therapeutics has traded in the range of $ 0.87 to $ 9.25 during the past year
What is the PE ratio of Outlook Therapeutics?
The price to earnings ratio of Outlook Therapeutics is -0.78
What is the reporting currency for Outlook Therapeutics?
Outlook Therapeutics reports financial results in USD
What is the latest annual profit for Outlook Therapeutics?
The latest annual profit of Outlook Therapeutics is USD -75.37M
What is the registered address of Outlook Therapeutics?
The registered address for Outlook Therapeutics is 800 NORTH STATE STREET, SUITE 304, DOVER, DELAWARE, 19901
What is the Outlook Therapeutics website address?
The website address for Outlook Therapeutics is www.outlooktherapeutics.com
Which industry sector does Outlook Therapeutics operate in?
Outlook Therapeutics operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
NSPRInspireMD Inc New
$ 3.67
(48.28%)
1.51M
LFWDLifeward Ltd
$ 1.29
(33.25%)
1.54M
CTXRCitius Pharmaceuticals Inc
$ 1.605
(24.90%)
418.62k
RETOReTo Eco Solutions Inc
$ 3.67
(20.33%)
2.44k
HLPHongil Group Inc
$ 1.03
(20.26%)
10.72k
FTRKFast Track Group
$ 2.0703
(-35.70%)
1.38M
GVHGlobavend Holdings Ltd
$ 1.02
(-18.41%)
26.8k
FBRXForte Biosciences Inc
$ 12.30
(-15.11%)
6.57k
ALLTAllot Ltd
$ 8.25
(-14.15%)
15.98k
AIFUAIFU Inc
$ 5.35
(-12.44%)
6.12k
AURAurora Innovations Inc
$ 5.4499
(0.27%)
4.26M
HCTIHealthcare Triangle Inc
$ 0.0339
(-0.29%)
3.35M
TNFATNF Pharmaceuticals Inc
$ 0.137
(5.38%)
2.55M
GNLNGreenlane Holdings Inc
$ 0.0087
(-3.33%)
2.34M
TSLLDirexion Daily TSLA Bull 2X Trust ETF
$ 13.51
(-0.84%)
2.17M

OTLK Discussion

View Posts
Mionaer1 Mionaer1 1 week ago
Norse 8 P=0.0043 after 12 weeks. The FDA will approve. This is not yet priced in. Gap close at $4.80 before August, 27 IMO. $10 after approval.
Bullish.
👍 2
H2R H2R 2 weeks ago
PT: $21 Ascendiant Capital Markets analyst Edward Woo reiterated a Buy rating on Outlook Therapeutics and adjusted the price target to $21. He emphasized that although the company currently generates no revenue, the commercial launch of LYTENAVA in Europe is expected to drive meaningful revenue growth starting in FY2025. Woo added that FDA approval remains a key near-term catalyst.

“We believe FDA approval for ONS-5010 is likely,” Woo stated. “The EU and UK launches validate the market opportunity and increase the product’s credibility. The current share price reflects uncertainty, not the potential upside if approval is granted in the U.S.”

https://prismmarketview.com/outlook-therapeutics-launches-lytenava-in-eu-and-uk-markets-for-the-treatment-of-wet-age-related-macular-degeneration/

Best of luck with your investments!
👍 1
H2R H2R 2 weeks ago
Potential for Gross Peak Sales of Over $600 Million

For Europe. Without any FDA approval.

What's the MC today? Yep...

Best of luck with your investments!
👍 1
H2R H2R 2 weeks ago
Pricing Established in Germany and UK

Initial Launch Market is quite interesting:



Interesting peak sales opportunity just for those 2 countries.

Best of luck with your investments!
👍 1
H2R H2R 2 weeks ago
SMC Recommendation of LYTENAVA™ for Wet AMD

The launch is on. I expect more PRs as the launch moves along

Best of luck with your investments!
👍 1
H2R H2R 3 weeks ago
More countries to come!

"[...]Going forward, we remain laser focused on ensuring success in Germany and the UK as well as preparing for additional launches across the region later this year and throughout 2026,” commented Jedd Comiskey, Senior Vice President, Head of Europe at Outlook Therapeutics.

Best of luck with your investments!
👍 2
H2R H2R 3 weeks ago
COMMERCIAL LAUNCH, UK & GERMANY!

Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced that LYTENAVA™ (bevacizumab gamma) is now commercially available in Germany and the UK for the treatment of wet age-related macular degeneration (wet AMD). LYTENAVA™ (bevacizumab gamma) is the first and only authorized ophthalmic formulation of bevacizumab for use in treating wet AMD in adults in the European Union and UK.

“We are excited to have launched LYTENAVA™ (bevacizumab gamma) for patients with wet AMD in Germany and the UK. I would like to extend sincere gratitude to the Outlook team and our partners for their commitment and dedication that helped to get us to this major milestone. Going forward, we remain laser focused on ensuring success in Germany and the UK as well as preparing for additional launches across the region later this year and throughout 2026,” commented Jedd Comiskey, Senior Vice President, Head of Europe at Outlook Therapeutics.

Off-label repackaged bevacizumab is one of the most frequently used first-line anti-VEGF treatments in Europe (approximately 2.8 million injections annually) and the United States (approximately 2.7 million injections annually) for the treatment of retinal diseases. ONS-5010/LYTENAVA™ has potential to mitigate certain risks associated with the current off-label use of repackaged bevacizumab.

Outlook Therapeutics has entered into a strategic collaboration with Cencora (formerly AmerisourceBergen) to support the commercial launch of LYTENAVA™ globally following regulatory approvals. The collaboration and integrated approach is designed to support market access and efficient distribution of LYTENAVA™ to benefit all stakeholders, including retina specialists, providers and patients in certain European markets and, if approved, in the United States.


https://ir.outlooktherapeutics.com/news-releases/news-release-details/outlook-therapeuticsr-announces-commercial-launch-lytenavatm

Best of luck with your investments!
👍 2
onebadz68 onebadz68 1 month ago
Why is the price going down after hours? They never mentioned what the offering is. 
👍 1
Pula Pula 1 month ago
They must dilute to pay kenyons bonuses. His incompetence is necessary to maintain critically necessary minimum incompetence to continue to paper shred everyones money for another decade to come. Its too bad there isnt an incompetence olympics. Kenyon trenary and evanson would all podium
👍️0
Grey_Ghost Grey_Ghost 1 month ago
Wow. Has a European distribution deal been finalized? Nice action today.
👍 3
glenn1919 glenn1919 1 month ago
OTLK..........................................https://stockcharts.com/h-sc/ui?s=OTLK&p=W&b=5&g=0&id=p86431144783
👍️0
dstock07734 dstock07734 1 month ago
Hello, sir,
I was wondering if you noticed the latest discovery of tumor-agnostic trial on rare pediatric cancers conducted by Masaryk University, Brno, Czechia which absolutely has connection with $NWBO's DC technology. I assume you knew it.

In case, you didn't. I listed some of the relevant info.

Here is the registry of the trial.
COMBINED ANTITUMOR THERAPY WITH EX VIVO MANIPULATED DENDRITIC CELLS PRODUCING INTERLEUKIN-12 IN CHILDREN,
ADOLESCENTS AND YOUNG ADULTS WITH PROGRESSIVE, RECURRENT OR PRIMARILY METASTATIC HIGH-RISK TUMORS
https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-003388-39/CZ
https://euclinicaltrials.eu/search-for-clinical-trials/?lang=en&EUCT=2024-516613-21-00

Here are the peer-review publications about the trial.
Personalized dendritic cell vaccine in multimodal individualized combination therapy improves survival in high-risk pediatric cancer patients
https://onlinelibrary.wiley.com/doi/10.1002/ijc.35062

Dendritic Cell-Based Immunotherapy in Advanced Sarcoma and Neuroblastoma Pediatric Patients: Anti-cancer Treatment Preceding Monocyte Harvest Impairs the Immunostimulatory and Antigen-Presenting Behavior of DCs and Manufacturing Process Outcome
https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2019.01034/full#supplementary-material

Assessment of Immune Response Following Dendritic Cell-Based Immunotherapy in Pediatric Patients With Relapsing Sarcoma
https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2019.01169/full

The results strike me as absolutely stunning. Note that poly-iclc was not included. Any only a few cases had Opdivo involved. All those patients had very serious medical conditions.

We analyzed data from all consecutive patients who received personalized DC vaccine between 2016 and 2022. Inclusion criteria were children and young adults, aged 0–20 years at diagnosis with relapsed/refractory and/or metastasizing high-risk solid tumors diagnosed in 2005–2021



We observed repeated recurrences or progressions, however, with favorable overall survival. Three- and five-year overall survival was 80.8% and 60.2%, and 60.4% and 30.2%, respectively, when calculated from the first progression. This is a notable outcome for such a high-risk cohort in comparison to historical data,21-26 where 3-year survival ranged from 15% to 30% and 5-year survival was generally
👍️ 1
Monksdream Monksdream 1 month ago
OTLK,under $2
👍️0
onebadz68 onebadz68 2 months ago
Any news would be greatly appreciated. EU sales etc
👍 2
Monksdream Monksdream 2 months ago
OTLK under $2
👍️0
pfelgueiras pfelgueiras 2 months ago
See more information about OTLK on Reddit atr/OTLK_Investors
👍 1
Monksdream Monksdream 2 months ago
OTLK under $2
👍 1
H2R H2R 2 months ago
Nice Day at OTLK

Not a great volume, but it moved up %9.43. Let's see what next week holds in store. It could be just a flash in the pan.

Best of luck with your investments!
👍 3
H2R H2R 2 months ago
PDUFA : August 27, 2025.

Thanks Mionaer1!!!

I completely missed the PR. That's some great news!

I'll check how to move some funds again this weekend.

Best of luck with your investments
👍️ 3
Mionaer1 Mionaer1 3 months ago



BLA accepted.BLA accepted.BLA accepted.

https://ir.outlooktherapeutics.com/news-releases/news-release-details/outlook-therapeuticsr-announces-acceptance-biologics-license-0
PDUFA August 27, 2025
👍️ 1
Mionaer1 Mionaer1 3 months ago
Back in. Fully diluted shares? 50M IMO. Am I right? Thanks.
👍 1
Mfgaumond Mfgaumond 3 months ago
Hahah. How you been Thermo? Any input on the current situation?
👍️ 2
thermo thermo 3 months ago
Lovely beach here.
👍️ 2
onebadz68 onebadz68 3 months ago
Perhaps thermo is having an extended stay at The White Lotus. 
👍 1
PieperIndy PieperIndy 3 months ago
So this board is dead lol? Got it.
👍 1
PieperIndy PieperIndy 3 months ago
Crickets chirp chirp. Friday news?
👍️0
PieperIndy PieperIndy 4 months ago
How you feeling about the latest moves @thermo
👍 1
OGBritbox OGBritbox 4 months ago
After the vote I’m predicting we will get some game changing news nobody saw coming. Hold onto your butts…..and shares
👍️ 1
glenn1919 glenn1919 4 months ago
OTLK................................................https://stockcharts.com/h-sc/ui?s=OTLK&p=W&b=5&g=0&id=p86431144783
👍️0
H2R H2R 4 months ago
Thanks OGBritbox!

For those who want the link, here it is:

https://ir.outlooktherapeutics.com/news-releases/news-release-details/outlook-therapeuticsr-re-submits-biologics-license-application-0

The ONS-5010 BLA resubmission is based on the efficacy and safety demonstrated in NORSE EIGHT, as well as additional chemistry, manufacturing and controls (CMC) information requested by the FDA. As previously announced, following Type A meetings with the FDA in Q4 CY2023 to address the ONS-5010 Complete Response Letter (CRL), the FDA informed Outlook Therapeutics that, in order to meet the FDA’s requirement for a second adequate and well-controlled clinical trial of ONS-5010, it could conduct a non-inferiority study evaluating ONS-5010 versus ranibizumab in a 12 week study of treatment naïve patients with a primary efficacy endpoint at 8 weeks (NORSE EIGHT). Outlook Therapeutics believes that the complete data set for NORSE EIGHT and the additional CMC information in the BLA resubmission, combined with the data from the other NORSE clinical trials, provides the required evidence to support approval of the ONS-5010 BLA in the United States.

A decision from the FDA is expected within six months.

Best of luck with your investments!
👍️ 1
OGBritbox OGBritbox 4 months ago
BLA has been resubmitted
👍️0
OGBritbox OGBritbox 4 months ago
Today I bought 10,000 more shares, bringing my total to just under 20,000 shares at an average of $4.
Very excited to see how the rest of the year plays out.
Extremely bullish
👍 3
KIPK KIPK 4 months ago
EX - Shame man. KARMA!!!
👍️0
H2R H2R 4 months ago
Upcoming Milestones

* Resubmission of the ONS-5010 BLA targeted for Q1 CY2025;
* Initial commercial launches in Germany and the UK planned to commence in Q2 CY2025; and
* Potential for US FDA approval of ONS-5010 in Q3 CY2025


ONS-5010 / LYTENAVA™ (bevacizumab-vikg) Biologics License Application (BLA) resubmission on track to meet target of Q1 CY2025
LYTENAVA™ (bevacizumab gamma) on track for first commercial launches in Germany and the United Kingdom (UK) planned for Q2 CY2025

ISELIN, N.J., Feb. 14, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union (EU) and the United Kingdom (UK) for the first authorized use of an ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (wet AMD), today announced financial results for the first quarter of fiscal year 2025 and provided a corporate update.

“With all of the recent progress made at Outlook Therapeutics and the upcoming milestones over the next few months, we expect to be a very different company by the end of 2025,” commented Lawrence Kenyon, Chief Financial Officer and Interim Chief Executive Officer of Outlook Therapeutics. “In 2025, we plan to start realizing our goal of providing patients, physicians and payers with an approved ophthalmic formulation of bevacizumab. This year, we anticipate beginning to generate the first revenue for Outlook Therapeutics with the launch of LYTENAVA™ in Germany and the UK and our BLA is on track for resubmission this quarter.”


* https://ir.outlooktherapeutics.com/news-releases/news-release-details/outlook-therapeuticsr-reports-financial-results-first-quarter-1

Best of luck with your investments!
👍️ 1
OGBritbox OGBritbox 4 months ago
To take advantage of the low price by getting a lot more shares for my money and lowering my cost average significantly.
👍 1
onebadz68 onebadz68 4 months ago
Why?
👍 1
OGBritbox OGBritbox 4 months ago
Bought a lot more the last 2 weeks
👍 2
onebadz68 onebadz68 4 months ago
I'm not sure either. Lol
Guess I'm just disappointed in myself for putting money on the wrong horse. 

I knew they'd be dilution but wow what a kick in the pocket book. From 60M to 260M shares not to mention more warrants. I know they said they have no plans to issue those additional shares but I've heard that before. 

I believe no decent investors are interested at this point unfortunately. 

One more mention, lol, $600K a year to run a company with 18 employees seems a bit excessive. 
👍 1
exwannabe exwannabe 4 months ago
Not sure what you expected here, this was already written once the trial fail crashed the price. That is one reason why some wanted to see the company resolve the liquidity issue months ago.

They can still turn this ship around., But it will be cold dark winter first. Hopefully, I am using "winter" in the literal sense.
👍 1
onebadz68 onebadz68 5 months ago
Can't believe no comments on the preliminary proxy statement. 
👍 1
H2R H2R 5 months ago
Dr. Jennifer Kissner's Excellent Presentation

This is the kind of presentation I enjoy. Very clear, well articulated. Overview of the data at 4 w, 8 w, 12 w, mean change in central retinal thickness data. Then the timeline for resubmittal and start of the clock...

I'm starting to feel pretty good about the likelihood of a possible FDA approval by September.

Best of luck with you investments!
👍 3
OGBritbox OGBritbox 5 months ago
Looks good for summer !
👍️ 3
H2R H2R 5 months ago
Thanks OGBritbox,

Funny, I took pretty much the exact same notes (except for the price in Euro :)) ) Glad you shared them on the board.

I'm posting them here, they recoup yours:

OTLK Conf with Larry Kenyon (I just listened to it live. I'll check if there is a recording)

1. H1 2025 to launch in Europe
2. NICE pricing: lowest OTLK pricing for approved products
3. Price ~ 560 Euro in the UK
4. FDA resubmittal in Q1 (the usual)
5. FDA decision expected before Sept 25. CMC, other CRL issues addressed.

The rest is pretty much the same as usual.

Cheers!

Best of luck with your investments!
👍 3
OGBritbox OGBritbox 5 months ago
Webinar highlights:
UK Price £472
Germany a few months after UK
IN USA: BLA submited in March 2025 and FDA have 180 days to take a decision.
They expect approval by FDA in September 2025

No wonder why they needed to sell some warrants. We should be seeing some money roll in from the EU by summer. Fingers crossed, as it’ll be great for SP
👍 2
H2R H2R 5 months ago
Lawrence A. Kenyon, CFO and Interim CEO of Outlook Therapeutics, will present at LIVE! with Webull Corporate Connect at the Healthcare Investment Webinar on Wednesday, January 29, 2025, at 2:00 PM ET.

#SaveTheDate! Lawrence A. Kenyon, CFO and Interim CEO of Outlook Therapeutics, will present at LIVE! with Webull Corporate Connect at the Healthcare Investment Webinar on Wednesday, January 29, 2025, at 2:00 PM ET.

Register here: https://t.co/R3OQAH46U8 $OTLK @WebullGlobal pic.twitter.com/dQe0jbPhfB— Outlook Therapeutics (@OutlookTx) January 27, 2025

Looking forward to hearing the interim CEO. Hopefully with news on two fronts:
* the FDA resubmittal status
* the European Launch status.

Best of luck with your investments!
👍 2
H2R H2R 5 months ago
FDA Resubmittal within 2 months

Thanks someconcerns for posting the Jan 23rd PR. Very interesting.

Under Russ Trenary, the Company executed on the plans within their PR deadlines. That has been quite consistent over the year. I would expect this behavior to continue under Lawrence Kenyon.

So when the January 23rd, 2025 PR states:
Outlook Therapeutics plans to resubmit the Biologics License Application (BLA) application for ONS-5010 in the first quarter of calendar 2025.
https://ir.outlooktherapeutics.com/news-releases/news-release-details/outlook-therapeuticsr-announces-presentation-efficacy-and-safety

which is in line with the January 16th, 2025 PR
“We believe that the statistically significant 12-week results for ONS-5010 in NORSE EIGHT, combined with the complete NORSE EIGHT data set, confirms our successful NORSE TWO pivotal study and will support the resubmission of our BLA in the United States for the treatment of wet AMD,” added Lawrence Kenyon, Chief Financial Officer and Interim Chief Executive Officer of Outlook Therapeutics. “Our team continues the necessary work for the planned resubmission of our BLA in the first quarter of calendar 2025.

and they have been planning for resubmittal since the beginning of Norse 8, I tend to believe they will deliver on their timeline.

Before the end of March, the Company should have resubmitted.

Best of luck with your investments!
👍 2
someconcerns someconcerns 5 months ago
Outlook Therapeutics® Announces Presentation of Efficacy and Safety Results from NORSE EIGHT Clinical Trial Evaluating ONS-5010 for the Treatment of Wet AMD

GlobeNewswire - 9:05 AM ET 1/23/2025 Investment News

Email Facebook. Twitter. LinkedIn. Print

Data presented at Hawaiian Eye and Retina 2025 Meeting
Results confirmed that intravitreal ONS-5010 provided early and sustained anatomic improvements, with steady gains in BCVA and reliable, consistent safety
ONS-5010 demonstrated to be non-inferior to Lucentis at 4 and 12 weeks
Company on track for anticipated BLA resubmission in calendar Q1 2025

ISELIN, N.J., Jan. 23, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. ( OTLK ) , a biopharmaceutical company that achieved regulatory approval in the European Union (EU) and the United Kingdom (UK) for the first authorized use of an ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (wet AMD), today announced the presentation of data from NORSE EIGHT at the Hawaiian Eye and Retina 2025 Meeting being held January 18-24, 2025 in Kauai, HI.

As part of the meeting, Baruch D. Kuppermann, MD, PhD, of Gavin Herbert Eye Institute, University of California, Irvine, CA presented the abstract titled, “ONS-5010 (bevacizumab-vikg) versus Ranibizumab for Neovascular Age-related Macular Degeneration: Results from the NORSE-EIGHT Noninferiority Randomized Trial,” highlighting the Company’s recently announced 12-week safety and efficacy results for the NORSE EIGHT clinical trial evaluating ONS-5010 in wet AMD patients.

Image: none

The NORSE EIGHT clinical trial was a randomized, controlled, parallel-group, masked, non-inferiority study of newly diagnosed, wet AMD subjects randomized in a 1:1 ratio to receive 1.25 mg ONS-5010 or 0.5 mg ranibizumab intravitreal injections. Subjects received injections at day 0 (randomization), week 4, and week 8 visits, and returned for a final study visit at week 12. The primary endpoint was mean change in BCVA from baseline to week 8.

“The NORSE EIGHT results provide additional evidence to the retina community that ONS-5010 meets the expectations for an ophthalmic formulation of bevacizumab, without the challenges that can arise from using repackaged, off-label formulations available today. The reductions in central retinal thickness observed in the trial confirmed that ONS-5010 reduced fluid in the retina on par with ranibizumab, and I’ve been encouraged with the consistency of this treatment across all NORSE clinical studies,” said Dr. Kuppermann.

Key Highlights

Mean BCVA at baseline was 58.8 ETDRS letters for the ONS-5010 group and 59.9 letters for the ranibizumab group.
ONS-5010 demonstrated mean BCVA improvements of +3.3, +4.2 and +5.5 letters at Months 1, 2, and 3 respectively.
The difference in mean BCVA between ONS-5010 and ranibizumab was -1.009 letters (95% confidence interval, -2.865, 0.848), meeting the noninferiority margin at Month 3 (p=0.0043) (applying the statistical parameters from the week 8 primary endpoint with the lower bound of the non-inferiority margin at -3.5 with a 95% confidence interval).
As previously announced, in the NORSE EIGHT trial, ONS-5010 did not meet the pre-specified non-inferiority endpoint at week 8 set forth in the special protocol assessment with the U.S. Food and Drug Administration (FDA).
Anatomical response was similar between treatments, with a reduction in central retinal thickness of -123.9 microns for ONS-5010 treated eyes and -127.3 microns for the ranibizumab group.
ONS-5010 was generally well-tolerated with overall ocular adverse event rates comparable to ranibizumab, with no cases of retinal vasculitis reported in either study arm. The most commonly reported adverse event (AE) was conjunctival hemorrhage, which occurred in 5 (2.5%) participants in each group.
Safety results demonstrated across the full duration of NORSE EIGHT are consistent with previously reported safety results from the NORSE ONE, NORSE TWO, and NORSE THREE clinical trials.

“Based on the data seen to date, we continue to be encouraged by the potential of ONS-5010 for the treatment of wet AMD. We believe that the complete data set from all of our NORSE clinical trials supports the resubmission of our BLA in the United States for the treatment of wet AMD, which we remain on track to complete this quarter,” added Lawrence Kenyon, Chief Financial Officer and Interim Chief Executive Officer of Outlook Therapeutics ( OTLK ).

Based on the completed analysis of the 12-week results, Outlook Therapeutics ( OTLK ) plans to resubmit the Biologics License Application (BLA) application for ONS-5010 in the first quarter of calendar 2025.

For more information about the NORSE EIGHT study, visit clinicaltrials.gov and reference identifier NCT06190093.

In the EU and the UK, ONS-5010/LYTENAVA™ (bevacizumab gamma) has already been granted Marketing Authorization. Outlook Therapeutics ( OTLK ) intends to continue efforts to begin launching in Europe in the first half of calendar 2025.

About ONS-5010 / LYTENAVA™ (bevacizumab-vikg, bevacizumab gamma)

ONS-5010/LYTENAVA™ is an ophthalmic formulation of bevacizumab for the treatment of wet AMD. LYTENAVA™ (bevacizumab gamma) is the subject of a centralized Marketing Authorization granted by the European Commission in the European Union (EU) and Marketing Authorization granted by the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom (UK) for the treatment of wet AMD.

In the United States, ONS-5010/LYTENAVA™ (bevacizumab-vikg) is investigational.

Bevacizumab-vikg (bevacizumab gamma in the EU and UK) is a recombinant humanized monoclonal antibody (mAb) that selectively binds with high affinity to all isoforms of human vascular endothelial growth factor (VEGF) and neutralizes VEGF’s biologic activity through a steric blocking of the binding of VEGF to its receptors Flt-1 (VEGFR-1) and KDR (VEGFR-2) on the surface of endothelial cells. Following intravitreal injection, the binding of bevacizumab to VEGF prevents the interaction of VEGF with its receptors on the surface of endothelial cells, reducing endothelial cell proliferation, vascular leakage, and new blood vessel formation in the retina.

About Outlook Therapeutics, Inc. ( OTLK )

Outlook Therapeutics ( OTLK ) is a biopharmaceutical company focused on the development and commercialization of ONS-5010/LYTENAVA™ (bevacizumab-vikg; bevacizumab gamma), for the treatment of retina diseases, including wet AMD. LYTENAVA™ (bevacizumab gamma) is the first ophthalmic formulation of bevacizumab to receive European Commission and MHRA Marketing Authorization for the treatment of wet AMD. Outlook Therapeutics ( OTLK ) is working to initiate its commercial launch of LYTENAVA™ (bevacizumab gamma) in the EU and the UK as a treatment for wet AMD, expected in the first half of calendar 2025. In the United States, ONS-5010/LYTENAVA™ is investigational, is being evaluated in an ongoing non-inferiority study for the treatment of wet AMD, and if successful, the data may be sufficient for Outlook to resubmit a BLA to the FDA in the United States. If approved in the United States, ONS-5010/LYTENAVA™, would be the first approved ophthalmic formulation of bevacizumab for use in retinal indications, including wet AMD.

Forward-Looking Statements

This press release contains forward-looking statements. All statements other than statements of historical facts are “forward-looking statements,” including those relating to future events. In some cases, you can identify forward-looking statements by terminology such as “anticipate,” “believe,” “continue,” “expect,” “may,” “plan,” “potential,” “will,” or “would” the negative of terms like these or other comparable terminology, and other words or terms of similar meaning. These include, among others, Outlook Therapeutics’ plans for commercial launch of LYTENAVA™ in the UK and EU and timing thereof, as well as the potential to launch with a partner, expectations concerning the therapeutic potential of LYTENAVA™ as a treatment of wet AMD, Outlook Therapeutics’ ability to remediate or otherwise resolve deficiencies identified in the CRL issued by the FDA, plans to resubmit the BLA for ONS-5010 and the timing thereof, Outlook Therapeutics’ commercialization strategy, expectations concerning decisions of regulatory bodies and the timing thereof, ONS-5010/LYTENAVA™’s potential as the first FDA-approved ophthalmic formulation of bevacizumab for use in treating retinal indications, including wet AMD, in the United States and other statements that are not historical fact. Although Outlook Therapeutics believes that it has a reasonable basis for the forward-looking statements contained herein, they are based on current expectations about future events affecting Outlook Therapeutics and are subject to risks, uncertainties and factors relating to its operations and business environment, all of which are difficult to predict and many of which are beyond its control. These risk factors include those risks associated with developing and commercializing pharmaceutical product candidates, risks of conducting clinical trials and risks in obtaining necessary regulatory approvals, the content and timing of decisions by regulatory bodies, the sufficiency of Outlook Therapeutics’ resources, as well as those risks detailed in Outlook Therapeutics’ filings with the Securities and Exchange Commission (SEC), including the Annual Report on Form 10-K for the fiscal year ended September 30, 2024, filed with the SEC on December 27, 2024, and future quarterly reports Outlook Therapeutics files with the SEC, which include uncertainty of market conditions and future impacts related to macroeconomic factors, including as a result of the ongoing overseas conflicts, high interest rates, inflation and potential future bank failures on the global business environment. These risks may cause actual results to differ materially from those expressed or implied by forward-looking statements in this press release. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Outlook Therapeutics does not undertake any obligation to update, amend or clarify these forward-looking statements whether as a result of new information, future events or otherwise, except as may be required under applicable securities law.

Investor Inquiries:
Jenene Thomas
Chief Executive Officer
JTC Team, LLC
T: 908.824.0775
OTLK@jtcir.com
Image: https://www.globenewswire.com/newsroom/ti?nf=OTMzNjQ4NiM2NzA2NzM0IzIwMjg4MjI=
Image: https://ml.globenewswire.com/media/NmJjMzk3ZTAtZmRiMC00NmZkLWIzOTgtZDI1YjI3OGZmYzk2LTEwNDAzOTM=/tiny/Outlook-Therapeutics-Inc-.png

Image: Primary Logo
Baruch D. Kuppermann, MD, PhD
Image: https://ml.globenewswire.com/media/1b88ce5b-691b-4ff4-8669-1d00607a0867/medium/baruch-d-kuppermann-md-phd.jpg

Baruch D. Kuppermann, MD, PhD
Source: Outlook Therapeutics, Inc. ( OTLK )
👍 3
H2R H2R 5 months ago
This is getting interesting!

https://ir.outlooktherapeutics.com/news-releases/news-release-details/outlook-therapeuticsr-announces-complete-twelve-week-efficacy



ONS-5010 demonstrated to be non-inferior to Lucentis at 12 weeks

BLA resubmission on track for calendar Q1 2025

Entered into agreements for warrant inducement transaction expected to result in up to $20.4 million in gross proceeds

ISELIN, N.J., Jan. 16, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Outlook Therapeutics, or the Company) (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union and the United Kingdom for the first authorized use of an ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (wet AMD), today announced it has completed the analysis of the complete 12-week safety and efficacy results for NORSE EIGHT, the second of two adequate and well controlled clinical trials evaluating ONS-5010 in wet AMD patients. ONS-5010 demonstrated noninferiority to ranibizumab at week 12 in the NORSE EIGHT trial. Based on the completed analysis of the 12-week results, Outlook Therapeutics plans to resubmit the Biologics License Application (BLA) for ONS-5010 in the first quarter of calendar 2025.

Julia A. Haller, MD, Ophthalmologist-in-Chief at Wills Eye Hospital and an Outlook Therapeutics Board member, commented, “The 3-month data from NORSE EIGHT provides additional evidence to confirm what retina specialists expected. The clinical trial continues to demonstrate that ONS-5010 injections result in immediate and sustained anatomic efficacy, with steady gains in visual acuity and reliable, consistent safety.”

The difference in the mean between ONS-5010 and ranibizumab was -1.009 best corrected visual acuity (BCVA) letters with a 95% confidence interval of (-2.865, 0.848) in the NORSE EIGHT trial. Applying the statistical parameters from the week 8 primary endpoint with the lower bound of the non-inferiority margin at -3.5 with a 95% confidence interval, the noninferiority margin was met at week 12 (p=0.0043), indicating that the two study arms are not different at this timepoint. In the intent-to-treat (ITT) population, NORSE EIGHT demonstrated a mean 5.5 letter improvement in BCVA in the ONS-5010 arm and 6.5 letter improvement in BCVA in the ranibizumab arm.

Mean change in BCVA at week 12 Non-Inferiority
ONS-5010 1.25 mg +5.5 letters 95%CI: (-2.865, 0.848)
P-value: 0.0043

Ranibizumab 0.5mg +6.5 letters

Additionally, the change in central retinal thickness, a measure of anatomical response, was similar in both study arms at all three study timepoints.

Mean change in central retinal thickness
Week 4 Week 8 Week 12
ONS-5010 1.25 mg -106.6 microns -117.7 microns -123.9 microns
Ranibizumab 0.5mg -108.4 microns -120.9 microns -127.3microns

As previously announced, in the NORSE EIGHT trial, ONS-5010 did not meet the pre-specified non-inferiority endpoint at week 8 set forth in the special protocol assessment (SPA) with the U.S. Food and Drug Administration (FDA). However, BCVA data across all study timepoints demonstrated an improvement in vision, increasing over time, and the presence of biologic activity. Overall, in NORSE EIGHT, ONS-5010 demonstrated mean visual acuity improvements of +3.3 letters at week 4, +4.2 letters at week 8, and +5.5 letters at week 12.

Additionally, in NORSE EIGHT, ONS-5010 was generally well-tolerated with overall ocular adverse event rates comparable to ranibizumab. The safety results demonstrated across the full duration of NORSE EIGHT are consistent with previously reported safety results from the NORSE ONE, NORSE TWO, and NORSE THREE clinical trials, with no cases of retinal vasculitis reported in either study arm.

“We believe that the statistically significant 12-week results for ONS-5010 in NORSE EIGHT, combined with the complete NORSE EIGHT data set, confirms our successful NORSE TWO pivotal study and will support the resubmission of our BLA in the United States for the treatment of wet AMD,” added Lawrence Kenyon, Chief Financial Officer and Interim Chief Executive Officer of Outlook Therapeutics. “Our team continues the necessary work for the planned resubmission of our BLA in the first quarter of calendar 2025. We remain confident in the potential of ONS-5010/LYTENAVA™ to provide an important therapy for the treatment of wet AMD in place of off-label repackaged bevacizumab that has not received regulatory approval for use in retinal diseases here in the United States.”

In the European Union and the United Kingdom, ONS-5010/LYTENAVA™ (bevacizumab gamma) has already been granted Marketing Authorization. Outlook Therapeutics intends to begin launching in Europe in the first half of calendar 2025.

Best of luck with your investments!
👍 2
thermo thermo 5 months ago
Certainly agree that showing non-inferiority at 12 wks was good. It doesn't erase the 8-wk primary end point miss but, if the FDA wants to approve, it gives them cover. It's far from a certainty but the market would be better off with this drug approved.

Also, many participants in the announced transaction will likely sell the common and hold the warrants. I estimate about 4 million shares for sale from the deal, so there will be some pressure on the stock for a while.
👍 5
OGBritbox OGBritbox 5 months ago
Great news!! I knew the 8 week preliminary was a fake news share grab. Looks like I have to average down some more due to additional dilution, but my bet is FDA is good to go
👍 2

Your Recent History

Delayed Upgrade Clock